Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis.

"Declarations Ethics approval and consent to participateAll patients provided written informed consent for study participation and publication of the scientific data obtained. This study was approved by the ethics committee of the University Hospital of Würzburg, Würzburg, Germany. The process of organising and conducting the study followed the principles of “Good Clinical Practice” [17, 18]. Conflict of interestDr. Schäfer reports personal fees from Amgen, AstraZeneca, and Novo Nordisk Pharma GmbH outside of the submitted work. Dr. Kovacs has nothing to disclose. Dr. Eder has nothing to disclose. Dr. Nigg has nothing to disclose. Dr. Feuchtenberger reports personal fees from AbbVie, Novartis, Roche, and UCB outside of the submitted work. All authors disclosed financial or nonfinancial interests that are directly or indirectly related to the work submitted for publication. Conflict of interest Dr. Schäfer reports personal fees from Amgen, AstraZeneca, and Novo Nordisk Pharma GmbH outside of the submitted work. Dr. Kovacs has nothing to disclose. Dr. Eder has nothing to disclose. Dr. Nigg has nothing to disclose. Dr. Feuchtenberger reports personal fees from AbbVie, Novartis, Roche, and UCB outside of the submitted work. All authors disclosed financial or nonfinancial interests that are directly or indirectly related to the work submitted for publication."